Literature DB >> 7863270

Early rheumatoid arthritis: therapeutic strategies.

P Emery1.   

Abstract

The early stage of rheumatoid arthritis (RA) is a unique and critical phase of disease which is often characterized by profound inflammation, severe symptomatology and a high likelihood of radiological progression. Decisions on treatment strategies need to be taken before irreversible damage and functional deterioration occur. There is evidence that early intervention with disease-modifying drugs may reduce functional deterioration and improve long-term outcome. Stable genetic markers and rheumatoid factor are useful in predicting disease severity and thus in identifying those patients who require early aggressive therapy. The acute phase response (APR) is a valuable marker of disease activity and catabolism in RA, and suppression of the APR improves outcome. The use of early aggressive therapy to suppress disease efficiently in patients with a poor prognosis should improve the long-term morbidity and mortality associated with RA.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7863270     DOI: 10.3109/03009749409095196

Source DB:  PubMed          Journal:  Scand J Rheumatol Suppl        ISSN: 0301-3847


  9 in total

1.  Prospective two year follow up study comparing novel and conventional imaging procedures in patients with arthritic finger joints.

Authors:  M Backhaus; G R Burmester; D Sandrock; D Loreck; D Hess; A Scholz; S Blind; B Hamm; M Bollow
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

2.  Can new diagnostic criteria of rheumatoid arthritis really make an early diagnosis? --A case report of early diagnosis and treatment of early rheumatoid arthritis with Chinese medicine.

Authors:  Yan-jun Kong; Qian-de Zhang; Mu-xin Wei
Journal:  Chin J Integr Med       Date:  2015-05-06       Impact factor: 1.978

3.  Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis.

Authors:  J M Albers; L Paimela; P Kurki; K B Eberhardt; P Emery; M A van 't Hof; F H Schreuder; M Leirisalo-Repo; P L van Riel
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

Review 4.  Remission, a therapeutic goal in inflammatory arthropathies? Clinical data from adalimumab studies.

Authors:  Carlomaurizio Montecucco
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Low field dedicated magnetic resonance imaging in untreated rheumatoid arthritis of recent onset.

Authors:  H Lindegaard; J Vallø; K Hørslev-Petersen; P Junker; M Østergaard
Journal:  Ann Rheum Dis       Date:  2001-08       Impact factor: 19.103

Review 6.  Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.

Authors:  Christine R Culy; Gillian M Keating
Journal:  Drugs       Date:  2002       Impact factor: 9.546

7.  Contrasting diagnosis performance of forced oscillation and spirometry in patients with rheumatoid arthritis and respiratory symptoms.

Authors:  Alvaro Camilo Dias Faria; Wellington Ribeiro Barbosa; Agnaldo José Lopes; Geraldo da Rocha Castelar Pinheiro; Pedro Lopes de Melo
Journal:  Clinics (Sao Paulo)       Date:  2012-09       Impact factor: 2.365

8.  Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure.

Authors:  Theresa Kapral; Tanja Stamm; Klaus P Machold; Karin Montag; Josef S Smolen; Daniel Aletaha
Journal:  Arthritis Res Ther       Date:  2006-02-24       Impact factor: 5.156

Review 9.  Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?

Authors:  Vasco Crispim Romão; Helena Canhão; João Eurico Fonseca
Journal:  BMC Med       Date:  2013-01-23       Impact factor: 8.775

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.